Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Bristol-Myers Squibb
Oscotec Inc.
National Institutes of Health Clinical Center (CC)
Shanghai Miracogen Inc.
NRG Oncology
Mayo Clinic
Rakuten Medical, Inc.
Memorial Sloan Kettering Cancer Center
Peking Union Medical College
Memgen, Inc.
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Hummingbird Bioscience
University of Pittsburgh
MediLink Therapeutics (Suzhou) Co., Ltd.
Sun Yat-sen University
Sun Yat-sen University
Hospital of Stomatology, Wuhan University
Shanghai Jiao Tong University School of Medicine
Shanghai Jiao Tong University School of Medicine
Beijing Tongren Hospital
Nanfang Hospital, Southern Medical University
Affiliated Cancer Hospital & Institute of Guangzhou Medical University